Continuous Intrathecal Milrinone Administration via IRRAflow Intraventricular Catheter for Refractory Cerebral Vasospasm in Subarachnoid Hemorrhage: A Case Report

经IRRAflow脑室内导管持续鞘内注射米力农治疗蛛网膜下腔出血并发难治性脑血管痉挛:病例报告

阅读:1

Abstract

BACKGROUND/OBJECTIVE: The IRRAflow device combines intracerebroventricular (ICV) medication infusion, cerebrospinal fluid (CSF) irrigation, and continuous intracranial pressure (ICP) monitoring. While ICV milrinone is conventionally given as a bolus to manage vasospasm after aneurysmal subarachnoid hemorrhage (aSAH), this case presents the use of continuous ICV milrinone infusion via IRRAflow in a patient with refractory cerebral vasospasm following aSAH. RESULTS: A 47-year-old female with aSAH (Hunt Hess 2, Modified Fisher Grade 4) underwent coil embolization for a ruptured left PICA aneurysm. Despite standard management, severe vasospasm was detected in the bilateral middle cerebral arteries and basilar arteries on hospital day 6. Following initiation of systemic milrinone IV and intra-arterial verapamil treatment, subsequent transcranial Doppler (TCD) and CT angiogram revealed persistent vasospasm. Elevated ICPs precluded further angiography or ICV bolus therapy through the existing external ventricular drain (EVD). An IRRAflow catheter was inserted intraventricularly for continuous CSF drainage and ICV milrinone administration (2.6 mg/kg/day). Over days 8 to 12, vasospasm improved significantly, ICP normalized, and neurologic examination permitted extubation. Continuous ICV milrinone therapy was tapered over 5 days, and the IRRAflow system removed on day 14 without complications, leading to discharge for acute rehabilitation. Patient consent for case publication was documented per institutional protocol. CONCLUSIONS: Continuous intrathecal milrinone infusion via IRRAflow may be a feasible adjunct for treating refractory vasospasm after aSAH. After the combined use of ICV milrinone via the IRRAflow catheter with standard-of-care therapies for severe vasospasm, the patient demonstrated favorable clinical and radiographic improvement without complications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。